Topic: Manufacturing Facilities
Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.
With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.
A Novartis ingredient operation in China is being hived off as the Swiss drugmaker continues its drive to cut manufacturing jobs.
South Korea’s JW Pharmaceutical has started targeting emerging markets with a deal for a plant in Vietnam.
South Korea's SK Holdings is rolling three API operations into a new unit, SK Pharmteco, and has put its headquarters in Sacramento, California.
Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up.
AveXis told the FDA during a facility inspection about some data errors, but the FDA ended up finding the situation "unremarkable."
India’s Natco Pharma, which just reported a substantial hit to its profits, today said it also has been issued a Form 483 for an API plant.
Mylan has spent more than $460 million buying Novartis cystic fibrosis products. Now, it wants the plant that makes them.
IDT Biologika has a new human vaccine manufacturing facility as its narrows its focus to the development and production of human vaccines only.